{"preliminary_commentary":{"by_channel":{"youtube":2,"x_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"PRIMAVERA","nct_id":"NCT06137144","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=primavera-nct06137144. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"PRIMAVERA","arms":[{"description":"Module 1 Cohort 1 evaluates safety, tolerability, efficacy of AZD3470 in r/r cHL participants with 2 prior lines of systemic anticancer therapy (including BV and anti-PD1). Participants will be treated according to protocol-defined windows.\n\nPart A (dose escalation) assesses AZD3470 at increasing doses in participants aged ≥18 years, r/r cHL.\n\nPart B (dose optimization/ expansion) includes participants at certain dose levels evaluated as tolerable in Part A and may include adolescent patients aged ≥12 years, upon SRC agreement.\n\nModule 1 Cohort 2 evaluates the safety, tolerability, efficacy of AZD3470 as consolidation for Stage III/IV cHL participants aged ≥50 years after CR or PR to frontline SOC therapy (either N-AVD, A-AVD, AVD, ABVD)\n\nModule 1 Cohort 3 evaluates the safety, tolerability, preliminary efficacy of AZD3470 in participants aged ≥18 years with r/r PTCL (PTCL NOS, ALCL, AITL subtypes) with at least 1 prior line of systemic anticancer therapy.","label":"AZD3470 Monotherapy","type":"EXPERIMENTAL"},{"description":"Module 2 Cohort 1 will assess participants aged ≥18 years with r/r cHL who have received at least one prior line of anticancer therapy. Participants will receive treatment according to the protocol-defined limit, or until disease progression, unacceptable toxicity as judged by the investigator or until meeting any other discontinuation criteria, as defined in the clinical study protocol, whichever occurs first.\n\nPart A (dose escalation) will evaluate the safety and tolerability of AZD3470 in combination with Pembrolizumab.\n\nPart B (dose optimization/expansion) will evaluate dose optimization/expansion in certain dose levels of AZD3470 in combination with Pembrolizumab, based on cumulative data from dose escalation part (Part A).","label":"AZD3470 in combination with Pembrolizumab","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2029-05-03","type":"ESTIMATED"},"conditions":["Lymphoma","Non-Hodgkin Lymphoma","Hodgkin Lymphoma","Peripheral T-cell Lymphoma (PTCL)","PTCL-NOS","ALCL","AITL"],"enrollment":{"count":161,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"AZD3470","otherNames":[],"type":"DRUG"},{"name":"Pembrolizumab","otherNames":["Keytruda"],"type":"DRUG"}],"last_update":"2026-10-13","lead_sponsor":"AstraZeneca","official_title":"A Modular Phase I/II, Open-label, Multicentre Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a PRMT5 Inhibitor, as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2029-05-03","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)","timeFrame":"From Screening continuously until 28 days after the last dose of study medication."},{"measure":"Incidence of DLTs (Dose Escalation Cohorts only)","timeFrame":"From first dose of AZD3470 to end of Cycle 1 (each cycle is 21 days)."}],"references":[],"start_date":{"date":"2024-01-23","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.","url":"https://clinicaltrials.gov/study/NCT06137144"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/primavera-nct06137144"}